
    
      Subjects who meet all eligibility criteria for Long Term Follow Up(LTFU) study participation
      at the ADT2002 End of Treatment(EOT) visit may continue LTFU for a maximum period of up to
      240 weeks post first dose of investigational product. No additional dosing will be
      administered on this LTFU protocol.
    
  